ImmuPharma (LON:IMM) Trading 28.8% Higher - Time to Buy?

Key Points

• ImmuPharma shares surged by 28.8%, reaching a high of GBX 15.23 ($0.21) during trading, which is a significant increase from its previous close of GBX 10.85 ($0.15).
• The company's market cap is currently £69.86 million with a highly negative price-to-earnings ratio of -1,570.67, indicating financial challenges.
• ImmuPharma specializes in developing peptide-based therapeutics for autoimmune diseases, with its lead program targeting Lupus.

ImmuPharma plc (LON:IMM - Get Free Report) shares shot up 28.8% during mid-day trading on Saturday . The company traded as high as GBX 15.23 ($0.21) and last traded at GBX 13.98 ($0.19). 44,749,293 shares changed hands during mid-day trading, an increase of 451% from the average session volume of 8,119,573 shares. The stock had previously closed at GBX 10.85 ($0.15).

ImmuPharma Stock Performance

The business has a fifty day moving average of GBX 3.12 and a 200-day moving average of GBX 2.92. The company has a market capitalization of £69.86 million, a P/E ratio of -1,570.67 and a beta of 1.53.

ImmuPharma (LON:IMM - Get Free Report) last issued its earnings results on Wednesday, August 6th. The company reported GBX (0.38) earnings per share (EPS) for the quarter. ImmuPharma had a negative return on equity of 131.41% and a net margin of 3,519.56%. Sell-side analysts anticipate that ImmuPharma plc will post -339.0000022 EPS for the current year.

ImmuPharma Company Profile

ImmuPharma PLC LSE AIM: IMM is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company's portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.